Fair Value Calculator Fair Value Calculator
EN DE

1875 (1875) Fair Value & Analysis

Healthcare · Market cap HK$2.5B

1 1875 1875 · HK
PriceHK$3.48
Fair ValueHK$0.6700
Upside-80.7%
Quality49/100
Watch 1875 for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range HK$0.5000 – HK$1.00

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −6.5% over the past month.

Price vs Fair Value (12 months)

HK$5.71 HK$1.71 Fair Value HK$0.6700 Jun 2025 Jul 2026

12‑month range HK$1.71 – HK$5.71 · fair‑value band HK$0.5000 – HK$1.00 · the HK$3.48 price screens above the HK$0.6700 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1875 (1875) currently trades at HK$3.48, while our model-based Fair Value estimate is HK$0.6700 — implying the stock looks roughly 80.7% overvalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 1875 generated revenue of HK$748M at a net margin of -13.4%. Revenue declined 55.3% year over year. It earns a return on equity of -14.8%. Net debt stands at HK$55.2M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$748M
Revenue growth (YoY) -55.3%
Net margin -13.4%
Return on equity -14.8%
Free cash flow −HK$26.9M FY2025
Operating margin -34.6%
More key figures
EPS (TTM) HK$0.0100
EPS growth (YoY) -87.1%
Net debt HK$55.2M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1875 reported revenue of HK$748M in FY2025 versus HK$76.3M in FY2021, a compound +76.9%/yr. Reported net income was −HK$100M in FY2025.

Revenue +76.9%/yr
FY21 HK$76.3M
FY22 HK$442M
FY23 HK$781M
FY24 HK$1.1B
FY25 HK$748M
Net income
FY21 −HK$261M
FY22 −HK$49.9M
FY23 −HK$37.8M
FY24 HK$34.8M
FY25 −HK$100M

Is 1875 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX 7,746 MXN 4,803 MXN -38%
Regeneron Pharmaceuticals, Inc REGN $635.45 $547.01 -14%
UCB SA UCB €274.90 €211.40 -23%
argenx SE ARGNF $900.00 $382.64 -57%
Alnylam Pharmaceuticals, Inc ALNY $291.22 $111.44 -62%
Samsung Biologics Co 207940 1,000,000 KRW 1,011,109 KRW +1%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 1875 (1875) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.6700 versus a price of HK$3.48 — about −81% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1875?
Our model-based fair value for 1875 is HK$0.6700 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$3.48.
What is the quality score of 1875?
1875 has a Quality Score of 49/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 1875 (1875)?
1875 reported trailing-twelve-month revenue of about HK$748M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 1875?
The net profit margin of 1875 is about -13.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.